Juan Carlos Izpisua Belmonte

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Juan Carlos Izpisua Belmonte
Juan Carlos Izpisua Belmonte 2018.jpg
Born1960 (age 61–62)
Hellín, Albacete, Spain
NationalitySpanish
Alma materUniversity of Valencia
University of Bologna
Scientific career
FieldsBiochemistry

Juan Carlos Izpisua Belmonte (born December 12, 1960, in Hellín, Albacete) is a Spanish biochemist and developmental biologist. He is a professor in the Gene Expression Laboratories at the Salk Institute for Biological Studies in La Jolla, California since 1993.

Education[edit]

Izpisua graduated from the University of Valencia, Spain with a bachelor's degree in Pharmacy and Science. He then earned a master's degree in Pharmacology from the same university before moving on to complete his Ph.D. in Biochemistry and Pharmacology at the University of Bologna, Italy and the University of Valencia, Spain. He followed that with a stage as a postdoctoral fellow in different institutions, including the European Molecular Biology Laboratory (EMBL), in Heidelberg, Germany and University of California, Los Angeles (UCLA), Los Angeles, USA prior to moving to the Salk Institute in 1993.[1]

Career[edit]

In 2004, he helped to establish the Center for Regenerative Medicine in Barcelona and was its Director between 2004 and 2014.[1][2] He is a main catalyzer in one of today's most promising areas of biomedicine: regenerative medicine. His work may help to discover new molecules and specific gene/cell treatments to prevent and cure diseases affecting mankind both in the adult and embryonic stages, as well as inducing endogenous in vivo regenerative responses that may allow for tissue and organ regeneration in humans. It also may contribute to increase our knowledge of aging and aging-associated diseases, thereby leading to healthier aging and increased lifespan.[3][4][5]

His conceptual discoveries and methodologies for regenerative medicine include:

  • Elucidating some of the key cellular and molecular bases of how an organism with millions of cells develops from a single cell embryo after fertilization.[6][7][8][9][10][11][12]
  • Seminal discoveries towards understanding the molecular basis underlying somatic cell reprogramming
  • New methodologies for the differentiation of human stem cells into various cells types and organoids, like the kidney and heart.[13][12][14][15]
  • Development of novel stem cell models of human aging and aging-associated diseases, and discovery of new drivers of rejuvenation.[13][16][17]
  • Novel genetic and epigenetic technologies to both treat, and prevent the transmission, of mitochondrial and nuclear DNA originated diseases.[13][18][19][20]
  • Proof of concept that iPSC technology can be used for the generation of disease corrected patient specific cells with potential value for cell therapy.[21]
  • The development of methodologies for culturing embryos, including non-human primates, and creating synthetic mammalian embryos.[22][23]
  • Development of technologies that allow differentiation of human cells inside embryos of different species. These results may allow for the generation of human tissues and organs.[24][25][26][27]

Belmonte has over 500 publications describing these results. He has also received several awards and honors over the years, a notable one was the naming of a secondary school, Instituto Enseñanza Secundaria (IES) Izpisua Belmonte, in his hometown of Hellín, Albacete, Spain.[28] In October, 2018, Belmonte was named by Time Magazine as one of the 50 Most Influential People in Healthcare of 2018.[29] Twice his work was among those selected by Science as the "Breakthrough of the Year," in 2008 for reprogramming and again in 2013 for the generation of mini-organs.[30][31]

As of September 2021 Google Scholar reports >52,000 citations for Juan Carlos Izpisua Belmonte, with an h-index of 119 and an i10-index of 365.[32]

See also[edit]

References[edit]

  1. ^ a b "Old Izpisua Belmonte Website". Archived from the original on 2012-01-25.
  2. ^ "CMRB Director".
  3. ^ "NYT Regeneration".
  4. ^ "NYT Aging".
  5. ^ "NYT Gene Editing".
  6. ^ "El Pais Regeneration".
  7. ^ "El Pais Asymmetry".
  8. ^ "El Pais Wing Gene".
  9. ^ "El Pais Gene".
  10. ^ "El Pais Chimera".
  11. ^ "El Pais Organoids".
  12. ^ a b "Stat Human Pig Chimera".
  13. ^ a b c "Salk Institute Profile".
  14. ^ "Nature Fanconi Anemia".
  15. ^ "Nature Medicine Wound Healing".
  16. ^ "SDUT Profile".
  17. ^ "New Yorker Aging".
  18. ^ "WP Gene Therapy".
  19. ^ "LAT Gene Editing".
  20. ^ "WP Gene Editing".
  21. ^ "Correcting Fanconi anaemia - healthy cells derived from diseased ones offer treatment hope". New York Stem Cell Foundation. Retrieved 2021-09-13.
  22. ^ "Artificial embryos draw closer with Salk Institute work in mice". San Diego Union-Tribune. 2019-10-18. Retrieved 2021-09-13.
  23. ^ Cyranoski, David (2019-10-31). "Primate embryos grown in the lab for longer than ever before". Nature. 575 (7781): 17–18. doi:10.1038/d41586-019-03326-5.
  24. ^ "Human Muscle Cells are Growing Inside of a Pig". Time. Retrieved 2021-09-13.
  25. ^ Wade, Nicholas (2017-01-26). "New Prospects for Growing Human Replacement Organs in Animals". The New York Times. ISSN 0362-4331. Retrieved 2021-09-13.
  26. ^ "Researchers have created embryos that are part-human and part-monkey". The Economist. 2021-04-15. ISSN 0013-0613. Retrieved 2021-09-13.
  27. ^ Hotz, Robert Lee (2021-04-26). "Creation of First Human-Monkey Embryos Sparks Concern". Wall Street Journal. ISSN 0099-9660. Retrieved 2021-09-13.
  28. ^ "IESIB".
  29. ^ "2018 Time Health Care 50".
  30. ^ Vogel, Gretchen (2008-12-19). "Reprogramming Cells". Science.
  31. ^ "Human Cloning at Last". Science. 2013-12-20.
  32. ^ "Juan Carlos Izpisua Belmonte". scholar.google.com. Retrieved 2021-09-13.